PTE

PolarityTE
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.8899
+0.0199
+2.29%
After Hours: 0.8800 -0.0099 -1.11% 17:43 05/22 EDT
OPEN
0.8900
PREV CLOSE
0.8700
HIGH
0.9000
LOW
0.8310
VOLUME
232.38K
TURNOVER
--
52 WEEK HIGH
7.07
52 WEEK LOW
0.7800
MARKET CAP
34.14M
P/E (TTM)
-0.2999
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average PTE stock price target is 3.500 with a high estimate of 5.00 and a low estimate of 3.000.

EPS

PTE News

More
Stocks That Hit 52-Week Lows On Friday
On Friday, 14 companies hit new 52-week lows.
Benzinga · 05/15 15:04
Cantor Fitzgerald Maintains Overweight on PolarityTE, Lowers Price Target to $3
Cantor Fitzgerald maintains PolarityTE (NASDAQ:PTE) with a Overweight and lowers the price target from $9 to $3.
Benzinga · 05/12 14:05
PolarityTE's (PTE) CEO David Seaburg on Q1 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 05/11 14:47
PolarityTE, Inc. 2020 Q1 - Results - Earnings Call Presentation
Seeking Alpha - Article · 05/11 14:35
PolarityTE Reports First Quarter 2020 Results
Business Wire · 05/11 12:00
PolarityTE: Q1 Earnings Insights
Shares of PolarityTE (NASDAQ:PTE) were flat in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 66.95% over the past year to ($0.39), which beat the estimate of ($0.52).
Benzinga · 05/11 11:42
PolarityTE Q1 EPS $(0.390) Beats $(0.520) Estimate
PolarityTE (NASDAQ:PTE) reported quarterly losses of $(0.390) per share which beat the analyst consensus estimate of $(0.520) by 25 percent. This is a 66.95 percent increase over losses of $(1.180) per share from the
Benzinga · 05/11 11:09
HC Wainwright & Co. Downgrades PolarityTE to Neutral
HC Wainwright & Co. downgrades PolarityTE (NASDAQ:PTE) from Buy to Neutral.
Benzinga · 05/04 11:16

Industry

Biotechnology & Medical Research
+1.01%
Pharmaceuticals & Medical Research
+0.05%

Hot Stocks

Symbol
Price
%Change

About PTE

PolarityTE, Inc., formerly Majesco Entertainment Company, is the owner of patent applications and know-how related to regenerative medicine and tissue engineering, as well as software applications used in diagnosis and treatment related to regenerative medicine. The Company seeks to develop and obtain regulatory approval for technology that will utilize a patient's own tissue substrates for the regeneration of skin, bone, muscle, cartilage, fat, blood vessels and nerves. The Company's PolarityTE platform simplifies regeneration and allows cells to function naturally. The platform can be applied across all cells, tissues and composite structures. The Company focuses on various products, including SkinTE, OsteoTE, AngioTE, MyoTE, CartTE, AdiposeTE and NeuralTE. The Company, through SkinTE, is focused on supplying an autologous construct to regenerate a patient’s skin due to a variety of injuries and conditions.
More

Webull offers kinds of Polarityte Inc stock information, including NASDAQ:PTE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PTE stock news, and many more online research tools to help you make informed decisions.